Moreover, in the Ma-Spore ALL cohort, we found that lower FOXO1 expression was associated with higher MRD burden post-induction remission therapy (P = 3.8 × 10−4 by Wilcoxon rank-sum test, Figure 4A). This evidence concerns the gene FOXO1 and acute lymphoblastic leukemia.